Definium (DFTX) CMO Daniel Karlin Receives 200,000-Share Award

What Happened

• Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), was reported as acquiring 200,000 common shares on 2026-09-14 as an award/grant. The shares were reported at $0.00 per share (total reported value $0) because they represent the settlement of performance share units, not a cash purchase.

Key Details

• Transaction date and price: 2026-09-14; grant/award recorded at $0.00 per share.
• Award type: Third tranche of performance share units (PSUs) granted effective March 12, 2025; each PSU is a contingent right to one common share subject to specified clinical and regulatory milestones (see footnote).
• Vesting conditions: Shares remain subject to vesting based on Karlin’s continued employment through March 12, 2028 and achievement of milestone criteria (per the Performance Share Unit Award Agreement).
• Additional note: Filing footnote states the reported amount includes 417 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.
• Shares owned after the transaction: Not disclosed in this filing.
• Timeliness: Report filed with a period/report date of 2026-09-14 (no late filing indicated).

Context

• These are performance-based equity awards (not an open-market buy or sale). They indicate potential future ownership if service and milestone conditions are met; they do not represent immediate cash value unless and until the PSUs vest and convert to shares. Such grants are common form of executive compensation and can dilute existing shareholders if they ultimately vest and are issued.